NASDAQ: GTHX



Next Generation Cancer Therapies

July 2020

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forwardlooking statements. Forward-looking statements in this presentation include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the U.S. for trilaciclib in SCLC, trilaciclib's possibility to improve patient outcomes across multiple indications, rintodestrant's potential to be best-in-class oral SERD, lerociclib's differentiated safety and tolerability profile over other marketed CDK4/6 inhibitors and the impact of pandemics such as COVID-19 (coronavirus), and are based on the company's expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company's actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in the company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available



Committed to improving lives and outcomes of people living with cancer

0

 \bigcirc



Differentiated oral CDK4/6

NASDAQ: GTHX

- 4

Lerociclib

inhibitor

Rintodestrant

Potential best-in-class oral SERD

Next-generation cancer therapies

Trilaciclib

First-in-class myelopreservation therapy



2020 – 2021: key milestones

TRILACICLIB

SMALL CELL LUNG CANCER

- ✓ NDA submission: June 2020
- ✓ U.S. commercial collaboration
- Commercial launch: 1H21

RINTODESTRANT

ER+, HER2- BC

- ✓ Initiate Phase 2 (palbociclib combination): 2Q20
- Monotherapy data update: 4Q20

LEROCICLIB

ER+, HER2- BC (+ fulvestrant)

- Development/commercialization partnership Greater China
- Data update: 3Q20

BREAST CANCER

- ✓ Initiate I-SPY 2 trial: 2Q20
- OS update from Phase 2 TNBC trial: 4Q20

COLORECTAL CANCER

- ✓ FDA pre-Phase 3 meeting
- Initiate Phase 3 trial: 4Q20

NASDAQ: GTHX | 5

What if we can improve the chemo experience for people living with cancer?



Current chemotherapy landscape

~1M U.S. patients receive chemotherapy annually



Chemotherapy remains the cornerstone of treatment for most cancers

Myelosuppression

is currently an unavoidable consequence of chemo that impacts patient safety, QoL and costs to the HC system





Patient experience of myelosuppression: burdensome and far-reaching

89%

OF CANCER PATIENTS

with myelosuppression rate it as having a moderate to major impact on their life* "...the overall fatigue was the worst. It stole my energy and joy for both life and family. It made me want to quit chemo numerous times."

"I don't feel like doing ANYTHING some days. It's like depression but completely physical. Of course, everyone's trying to be supportive. And I have my own obligations, but I feel like a burden."

"...it so happened I had a father dying in the hospital and I was strictly forbidden from entering a hospital (except my own)."



*Impact of chemotherapy-induced myelosuppression on daily living: result of U.S. online survey of patients with cancer ISPOR 2020 Congress Poster: Epstein et al, Poster# PCN333 or Smart Poster (mobile optimized)

Our solution: Trilaciclib

First-in-class

myelopreservation therapy that has the potential to make chemotherapy safer, improve the patient experience, and in some settings, help patients live longer



Our solution: trilaciclib



30-minute IV infusion prior to chemo; **given first time and every time** chemo is administered



Preserves bone marrow and immune system function from damage by chemo



Protects patients from the dangerous side effects of myelosuppression



In some settings, may help patients live longer



Can be **incorporated into multiple chemo regimens**, including I/O + chemo Breakthrough
Therapy
Designation for
SCLC

NDA submitted
June 2020



Body of evidence in SCLC: three randomized trials

Trilaciclib reduces chemotherapyrelated toxicity and need for rescue interventions

- ✓ Significant improvement in patient experience, notably less fatigue
- ✓ Less neutropenia and anemia
- ✓ Reduced G-CSF usage and transfusions

Three randomized, placebo-controlled, double-blind trials in: 1st-line SCLC (+ etop/carbo), 1st-line SCLC (+ etop/carbo/Tecentriq), 2nd/3rd-line SCLC (+ topotecan)



Improved treatment experience in SCLC

Patient survey findings*

(patients not enrolled in trilaciclib trials)

- 88% of SCLC respondents reported that myelosuppression had moderate to major impact on their life
- Of those, 63% noted fatigue as their biggest myelosuppressive issue
- Of those who noted fatigue, average rating of 8.4 on 10-point scale of how bothersome fatigue was

Patient Reported Outcomes data (n=235)

(pooled from three randomized, placebo-controlled, double-blind trials)

Subscale	< <trilaciclib better<="" th=""><th>Placebo Better>></th><th>Hazard Ratio (95% CI)</th></trilaciclib>	Placebo Better>>	Hazard Ratio (95% CI)
Fatigue	├		0.56 (0.37, 0.85)
Functional Well-being	├ → -		0.44 (0.28, 0.70)
Physical Well-being	├ → -		0.62 (0.39, 0.97)
Anemia – Trial Outcome Index	├─ ◆── 		0.53 (0.34, 0.83)
Functional Assessment of Cancer Treatment - Anemia	├── →		0.46 (0.29, 0.72)

Updated from data presented at MASCC 2019



*Impact of chemotherapy-induced myelosuppression on daily living: result of U.S. online survey of patients with cancer ISPOR 2020 Congress Poster: Epstein et al, Poster# PCN333 or Smart Poster (mobile optimized)

Significant multi-lineage myelopreservation benefits support improved patient experience*

		PLACEBO + CHEMO	TRILA + CHEMO	
	Patients (intent-to-treat population)	119	123	P-VALUE**
Neutrophils	Mean duration (days) of severe neutropenia in cycle 1 (SD)	4 (5.1)	0 (1.8)	<0.0001
	Occurrence of severe neutropenia	63 (52.9%)	14 (11.4%)	<0.0001
	Occurrence of G-CSF administration	67 (56.3%)	35 (28.5%)	<0.0001
	Incidence of G-CSF administration (event rate per 100 cycles)	40.6	16.4	<0.0001
Red Blood Cells	Occurrence of Grade 3/4 anemia	38 (31.9%)	25 (20.3%)	0.0279
	Occurrence of ESA administration	14 (11.8)	4 (3.3%)	0.0254
	Occurrence of RBC transfusions on/after 5 weeks	31 (26.1%)	18 (14.6%)	0.0252
	Incidence of RBC transfusions on/after 5 weeks (event rate per 100 weeks)	3.1	1.5	0.0027
Platelets	Occurrence of Grade 3/4 thrombocytopenia	43 (36.1%)	24 (19.5%)	0.0067



*Adapted from: Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer <u>ASCO 2020 Congress Poster: Weiss et al</u>, Poster #384 or <u>Smart Poster</u> (mobile optimized)

**2-sided p-value; pooled data from three randomized, placebo-controlled, double-blind SCLC trials

Preparing to bring trilaciclib to SCLC patients

U.S.

NDA submitted June 2020

Building functional capabilities in U.S.



Co-promotion agreement with experienced Boehringer Ingelheim oncology sales force

Ex-U.S.

Evaluating partnership opportunities to commercialize trilaciclib ex-U.S.



Pursuing additional indications: breast cancer

Preliminary survival benefit observed in mTNBC randomized trial



- ✓ Patients able to tolerate more cycles of chemo, without increased toxicity
- ✓ Reduced rate of RBC transfusions
- Patient-reported outcomes data support improved patient experience
- ✓ Significant improvement in OS



Preliminary overall survival benefit in mTNBC

	Control (GC only) (Group 1)	Trilaciclib + GC (Group 2)	Trilaciclib + GC (Group 3)	Trilaciclib + GC (Group 2+3)
ITT population	N = 34	N = 33 N = 35		N = 68
Median OS (months)	12.6	20.1	17.8	20.1
HR		0.33	0.34	0.36
p-value		0.028	0.0023	0.0015
Median PFS (months)	5.7	9.4	7.3	8.8
HR		0.60	0.59	0.59
p-value		0.13	0.12	0.063

Hypothesis: trilaciclib's preservation of immune system function during chemo drives OS benefit



Group 1: GC only (Day 1/8) (n=34); Group 2: trilaciclib + GC (Day 1/8) (n=33); Group 3: trilaciclib only (Day 1/8), trilaciclib + GC (Day 2/9) (n=35) Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized Phase 2 trial ESMO 2019 Oral Presentation: O'Shaugnessey et al, Abstract #6255; results published concurrently in *The Lancet Oncology*

Next step in breast cancer: I-SPY 2 neoadjuvant trial

Goals of Phase 2 trial


- Evaluate trilaciclib in broadly-used chemo regimens (e.g. Taxol + AC)
- Evaluate trilaciclib in all breast cancer sub-types (ER+, HER2+, TNBC)
- Evaluate impact of trilaciclib on tumor immune microenvironment +/- PD-1
- Endpoints: biomarkers, efficacy and myelopreservation

Neoadjuvant breast cancer with high risk of recurrence → could be any HR or HER2 status (10 biomarker subtypes)

Four-arm Bayesian design

Chemotherapy + trilaciclib





AC = adriamycin and cyclophosphamide

* Taxol + PD-1 followed by AC will potentially be historical data



Opportunity to improve patient outcomes across multiple indications

~1 million* patients in planned indications

69,000

>350,000

>600,000

Colorectal Cancer

20,000

Metastatic Triple-Negative Breast Cancer

Small Cell Lung Cancer

Adjuvant Breast Cancer

GO

Next steps for trilaciclib across multiple indications

SCLC

- Completed NDA submission in June 2020
- PDUFA date assigned in August 2020 (pending acceptance)

Breast Cancer

- Initiated I-SPY2 trial in 2Q20
- Updated OS data from mTNBC trial in 4Q20

Colorectal Cancer

- Completed FDA pre-Phase 3 meeting
- Initiate Phase 3 trial in 4Q20





Trilaciclib

First-in-class myelopreservation therapy

Rintodestrant

Potential best-in-class oral SERD

GO



Differentiated oral CDK4/6 inhibitor

Improving options for ER+, HER2- breast cancer

- ER degradation shown to be most effective means of blocking estrogen signaling in ER+, HER2- breast cancer
- Only available SERD is fulvestrant painful intramuscular injections

Opportunity to improve options in first-line and adjuvant settings with oral SERD



Rintodestrant Phase 1 data: well tolerated with proof-of-concept anti-tumor activity

Well tolerated; favorable safety profile observed at all dose levels

No dose-limiting toxicities observed; maximum tolerated dose not reached

AEs mostly Grade 1, no bradycardia or cytopenias

¹⁸F-FES PET scans: **ER occupancy ≥ 80%** in doses ≥ 600 mg

Preliminary evidence of anti-tumor activity in heavily pre-treated population



Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC). <u>ESMO 2019 Poster: Dees et al</u>, Abstract #3587

Assessing the potential of rintodestrant

Phase 1/2a program w/ ~100 patients enrolled by YE20: additional data 4Q20

- 67 patients enrolled in Phase 1/2a trial, including expansion cohorts of 600 mg and 1,000 mg monotherapy
- Based on totality of data, 800 mg QD selected as dose for further development
- Initiated additional arm in 2Q20 (~40 patients) to evaluate rintodestrant (800 mg) + palbociclib



Significant potential to improve ER+ breast cancer treatment

>450,000 2L, 1L, and adjuvant ER+ BC patients globally





*Source: secondary epi sources, Decision Resources Group 2027 estimates for U.S., EU5 and Japan **Duration estimates based on similar trial results in the same or similar patient populations as planned trials

NASDAQ: GTHX

25

Next-generation cancer therapies

Trilaciclib

First-in-class myelopreservation therapy

Rintodestrant

Potential best-in-class oral SERD

Lerociclib

Differentiated oral CDK4/6 inhibitor



Lerociclib: differentiated oral CDK4/6 inhibitor

	DOSE-LIMITING NEUTROPENIA	MONITORING REQUIREMENT	DOSING HOLIDAY	QT PROLONGATION	DILI	GRADE 3/4 DIARRHEA	VTE
lbrance®	x	X	x	-	-	-	-
Kisqali®	X	X	Х	X	X	-	-
Verzenio®	x	X	—	-	X	Х	x
lerociclib	-	Potential for less monitoring	-	_	-	_	-
Differentiated PK and				ential for less			

tolerability profile

Continuous dosing (no holiday) with fewer dose-limiting toxicities Potential for less CBC monitoring, reducing patient & physician burden



Clinical overview: improved safety and tolerability profile

Phase 1b/2 trial: 110 patients lero + fulvestrant (similar entry criteria to PALOMA 3) Low rates of Grade 4 neutropenia **without a drug holiday**

Low rates of stomatitis and alopecia across all dose levels

65.2% clinical benefit rate; median progression-free survival of 15 months (immature) **Updated data 3Q20** supporting 150 mg BID as go forward dose



Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer. <u>SABCS 2019: Bulat et al</u>, Abstract #P1-19-17 or <u>Smart Poster</u> (mobile optimized)

G1 Therapeutics: improving outcomes in cancer treatment



Trilaciclib: near-term opportunity to improve outcomes for patients receiving chemo



Rintodestrant: potential best-in-class oral SERD



Rights to all compounds provides multiple options for valuecreating partnerships



Well funded with cash runway into 2022



NASDAQ: GTHX


10.20



Appendix

Potential to improve outcomes across tumor types

Trilaciclib used first time, and every time, patient receives chemotherapy





*Source: Secondary epi sources, 2027 estimates

**EP refers to any regimen that includes etoposide + platinum; GC refers to gemcitabine/carboplatin; Taxol AC refers to Taxol + Adriamycin and cyclophosphamide; 5-FU refers to any regimen that includes fluorouracil (e.g., FOLFOX). In addition to CRC, pancreatic cancer, gastroesophageal cancer and squamous cell carcinoma of the head and neck (SCCHN) are also treated with 5-FU regimens (% currently treated with 5-FU regimens varies by tumor type and region)

***Source: SCLC and TNBC: G1 Therapeutics' completed trials; CRC and Adjuvant BC: number of cycles for eligible chemo regimens from Decision Resources Group Treatment Landscape and Forecast Assumptions 2019 Reports (CRC and BC)